Oral transmucosal fentanyl citrate as breakthrough pain relieving medication: A pilot study
ABSTRACT Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management strategies often fail to provide adequate relief. Oral transmucosal fentanyl citrate (OTFC) has emerged as a rapid-onset opioid...
Saved in:
Published in | Current medicine research and practice Vol. 14; no. 4; pp. 145 - 149 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Medknow Publications and Media Pvt. Ltd
01.07.2024
Wolters Kluwer Medknow Publications |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ABSTRACT Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management strategies often fail to provide adequate relief. Oral transmucosal fentanyl citrate (OTFC) has emerged as a rapid-onset opioid analgesic, offering a potential solution for managing this challenging condition in home care settings. Aims: This study aims to evaluate the efficacy of OTFC in managing breakthrough pain and its effects on the quality of life in cancer patients treated at home. Materials and Methods: A pilot study was conducted with 40 cancer patients experiencing more than one episode of breakthrough pain daily. These patients were administered OTFC 400 μg for pain management. Degree of pain (NRS) and modified ‘Quality of Well-being' (QWB) scores were analysed using data filled in by patients. Data were collected and analysed using paired t-tests to compare pre- and post-treatment scores. Results: The administration of OTFC resulted in a significant reduction in pain, as indicated by the decrease in NRS scores from 9.9 ± 0.304 to 0.5 ± 0.906 within 30 minutes (P < 0.0001). Additionally, there was a marked improvement in QWB scores, which increased from 26.18 ± 2.8 to 36.3 ± 3.16 over the same period (P < 0.001). Mild side effects, such as nausea, headache, and somnolence, were reported, but no serious adverse events were observed. Conclusions: We conclude that OTFC 400 μg is an effective and well-tolerated option for managing breakthrough pain in cancer patients and in improving the quality of life in home care settings. Keywords: Breakthrough pain, cancer pain, fentanyl citrate, opioids, oral transmucosal fentanyl citrate, rapid onset |
---|---|
AbstractList | ABSTRACT Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management strategies often fail to provide adequate relief. Oral transmucosal fentanyl citrate (OTFC) has emerged as a rapid-onset opioid analgesic, offering a potential solution for managing this challenging condition in home care settings. Aims: This study aims to evaluate the efficacy of OTFC in managing breakthrough pain and its effects on the quality of life in cancer patients treated at home. Materials and Methods: A pilot study was conducted with 40 cancer patients experiencing more than one episode of breakthrough pain daily. These patients were administered OTFC 400 μg for pain management. Degree of pain (NRS) and modified ‘Quality of Well-being' (QWB) scores were analysed using data filled in by patients. Data were collected and analysed using paired t-tests to compare pre- and post-treatment scores. Results: The administration of OTFC resulted in a significant reduction in pain, as indicated by the decrease in NRS scores from 9.9 ± 0.304 to 0.5 ± 0.906 within 30 minutes (P < 0.0001). Additionally, there was a marked improvement in QWB scores, which increased from 26.18 ± 2.8 to 36.3 ± 3.16 over the same period (P < 0.001). Mild side effects, such as nausea, headache, and somnolence, were reported, but no serious adverse events were observed. Conclusions: We conclude that OTFC 400 μg is an effective and well-tolerated option for managing breakthrough pain in cancer patients and in improving the quality of life in home care settings. Keywords: Breakthrough pain, cancer pain, fentanyl citrate, opioids, oral transmucosal fentanyl citrate, rapid onset Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management strategies often fail to provide adequate relief. Oral transmucosal fentanyl citrate (OTFC) has emerged as a rapid-onset opioid analgesic, offering a potential solution for managing this challenging condition in home care settings. This study aims to evaluate the efficacy of OTFC in managing breakthrough pain and its effects on the quality of life in cancer patients treated at home. A pilot study was conducted with 40 cancer patients experiencing more than one episode of breakthrough pain daily. These patients were administered OTFC 400 μg for pain management. Degree of pain (NRS) and modified ‘Quality of Well-being' (QWB) scores were analysed using data filled in by patients. Data were collected and analysed using paired t-tests to compare pre- and post-treatment scores. The administration of OTFC resulted in a significant reduction in pain, as indicated by the decrease in NRS scores from 9.9 ± 0.304 to 0.5 ± 0.906 within 30 minutes (P < 0.0001). Additionally, there was a marked improvement in QWB scores, which increased from 26.18 ± 2.8 to 36.3 ± 3.16 over the same period (P < 0.001). Mild side effects, such as nausea, headache, and somnolence, were reported, but no serious adverse events were observed. We conclude that OTFC 400 μg is an effective and well-tolerated option for managing breakthrough pain in cancer patients and in improving the quality of life in home care settings. Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management strategies often fail to provide adequate relief. Oral transmucosal fentanyl citrate (OTFC) has emerged as a rapid-onset opioid analgesic, offering a potential solution for managing this challenging condition in home care settings. Aims: This study aims to evaluate the efficacy of OTFC in managing breakthrough pain and its effects on the quality of life in cancer patients treated at home. Materials and Methods: A pilot study was conducted with 40 cancer patients experiencing more than one episode of breakthrough pain daily. These patients were administered OTFC 400 μg for pain management. Degree of pain (NRS) and modified ‘Quality of Well-being’ (QWB) scores were analysed using data filled in by patients. Data were collected and analysed using paired t-tests to compare pre- and post-treatment scores. Results: The administration of OTFC resulted in a significant reduction in pain, as indicated by the decrease in NRS scores from 9.9 ± 0.304 to 0.5 ± 0.906 within 30 minutes (P < 0.0001). Additionally, there was a marked improvement in QWB scores, which increased from 26.18 ± 2.8 to 36.3 ± 3.16 over the same period (P < 0.001). Mild side effects, such as nausea, headache, and somnolence, were reported, but no serious adverse events were observed. Conclusions: We conclude that OTFC 400 μg is an effective and well-tolerated option for managing breakthrough pain in cancer patients and in improving the quality of life in home care settings. |
Audience | Academic |
Author | Dua, Naresh Dua, Shubh Annaram, Randheer Kumar Jain, Pradeep Yadav, Priya Sood, Jayashree |
Author_xml | – sequence: 1 fullname: Dua, Naresh – sequence: 2 fullname: Annaram, Randheer Kumar – sequence: 3 fullname: Jain, Pradeep – sequence: 4 fullname: Yadav, Priya – sequence: 5 fullname: Dua, Shubh – sequence: 6 fullname: Sood, Jayashree |
BookMark | eNptUU1rGzEQ1SGFpmnOuQpytqORtLtSbiY0jSGQS3vqQYz14SjZlYy0LvjfR4lDQ6AMzDCPN4_HvG_kJOXkCbkAtpTAxJWdym752szADZcn5JSLji-YguErOa_1iTEGWmgN-pT8eSg40rlgqtPe5tqW4NOM6TBSGxs-e4qVborH5_mx5P32ke4wJlr8GP3fmLZ08i5anGNO13RFd3HMM63z3h2-ky8Bx-rP3-cZ-X3749fN3eL-4ef6ZnW_sBykXKhBKxeUE4MMQnKuuQ68Y53ETgU2cOYHboUH2DjQzTlXknnHwUHf9WyjxBlZH3VdxiezK3HCcjAZo3kDctkaLHO0ozfQbWzve48qoJSAWmsbFJdWSd2jg6Z1edTaYqPHFHL7gZ1itWalQAMHrURjLf_DauX8FG2LI8SGfzq4Oh7YkmstPvyzCcy8pmbeAvtITbwAONSPTQ |
Cites_doi | 10.1016/S0304-3959(98)00179-1 10.2147/nano.2007.2.1.49 10.2147/CEOR.S52273 10.1016/j.jpainsymman.2012.09.009 10.1038/sj.bjc.6603811 10.3389/fpain.2022.893530 10.1089/jpm.2008.9922 10.1097/AJP.0b013e3181c4458a 10.3390/jcm9041003 10.1111/j.1526-4637.2005.00045.x 10.2165/00003088-200241090-00003 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd. |
Copyright_xml | – notice: COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd. |
DBID | AAYXX CITATION DOA |
DOI | 10.4103/cmrp.cmrp_72_24 |
DatabaseName | CrossRef Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
EndPage | 149 |
ExternalDocumentID | oai_doaj_org_article_15bc6e6ea8fa441a999cf824c8496ad1 A819121983 10_4103_cmrp_cmrp_72_24 |
GroupedDBID | 0R~ 4.4 457 AACTN AAEDT AAKOC AALRI AAXUO AAYXX ABDBF ABMAC ACDAQ ACGFS ADPAM AFTJW AIKHN AITUG ALMA_UNASSIGNED_HOLDINGS BELOY BKOJK CITATION EBS EJD FDB GROUPED_DOAJ H13 HZ~ IAO IHR ITC KOM M41 O9- OK1 OVD RMW ROL SPCBC SSZ TEORI W3E |
ID | FETCH-LOGICAL-c2144-8798df8d374f3422929f25054a58f0720e72c3e11bd190192840ed21d16560b83 |
IEDL.DBID | DOA |
ISSN | 2352-0817 |
IngestDate | Mon Oct 28 19:37:34 EDT 2024 Wed Dec 11 16:51:38 EST 2024 Tue Dec 10 03:41:34 EST 2024 Fri Dec 06 08:35:27 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2144-8798df8d374f3422929f25054a58f0720e72c3e11bd190192840ed21d16560b83 |
OpenAccessLink | https://doaj.org/article/15bc6e6ea8fa441a999cf824c8496ad1 |
PageCount | 5 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_15bc6e6ea8fa441a999cf824c8496ad1 gale_infotracmisc_A819121983 gale_infotracacademiconefile_A819121983 crossref_primary_10_4103_cmrp_cmrp_72_24 |
PublicationCentury | 2000 |
PublicationDate | 20240701 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: 20240701 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Current medicine research and practice |
PublicationYear | 2024 |
Publisher | Medknow Publications and Media Pvt. Ltd Wolters Kluwer Medknow Publications |
Publisher_xml | – sequence: 0 name: Medknow Publications and Media Pvt. Ltd – name: Wolters Kluwer Medknow Publications |
References | Bossi (R1-20240901) 2022; 3 Bornemann-Cimenti (R3-20240901) 2013; 110 Cuomo (R2-20240901) 2020; 9 Darbà (R14-20240901) 2013; 6 Bilen (R13-20240901) 2010; 22 Zhang (R11-20240901) 2002; 41 Jandhyala (R15-20240901) 2013; 46 Mercadante (R7-20240901) 2007; 96 Aronoff (R10-20240901) 2005; 6 Portenoy (R5-20240901) 1999; 79 Gordon (R8-20240901) 2008; 11 Mercadante (R4-20240901) 2010; 26 Mystakidou (R9-20240901) 2007; 2 |
References_xml | – volume: 79 start-page: 303 year: 1999 ident: R5-20240901 article-title: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients:A controlled dose titration study publication-title: Pain doi: 10.1016/S0304-3959(98)00179-1 contributor: fullname: Portenoy – volume: 2 start-page: 49 year: 2007 ident: R9-20240901 article-title: Oral transmucosal fentanyl citrate in cancer pain management:A practical application of nanotechnology publication-title: Int J Nanomedicine doi: 10.2147/nano.2007.2.1.49 contributor: fullname: Mystakidou – volume: 6 start-page: 1 year: 2013 ident: R14-20240901 article-title: Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain publication-title: Clinicoecon Outcomes Res doi: 10.2147/CEOR.S52273 contributor: fullname: Darbà – volume: 22 start-page: 103 year: 2010 ident: R13-20240901 article-title: Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate publication-title: Agri contributor: fullname: Bilen – volume: 46 start-page: 573 year: 2013 ident: R15-20240901 article-title: Efficacy of rapid-onset oral fentanyl formulations versus oral morphine for cancer-related breakthrough pain:A meta-analysis of comparative trials publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2012.09.009 contributor: fullname: Jandhyala – volume: 96 start-page: 1828 year: 2007 ident: R7-20240901 article-title: Transmucosal fentanyl versus intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603811 contributor: fullname: Mercadante – volume: 3 start-page: 893530 year: 2022 ident: R1-20240901 article-title: Rapid-onset opioids for management of breakthrough cancer pain:Considerations for daily practice publication-title: Front Pain Res (Lausanne) doi: 10.3389/fpain.2022.893530 contributor: fullname: Bossi – volume: 11 start-page: 633 year: 2008 ident: R8-20240901 article-title: Oral transmucosal fentanyl citrate –OTFC (ACTIQ) #103 publication-title: J Palliat Med doi: 10.1089/jpm.2008.9922 contributor: fullname: Gordon – volume: 26 start-page: 306 year: 2010 ident: R4-20240901 article-title: The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen publication-title: Clin J Pain doi: 10.1097/AJP.0b013e3181c4458a contributor: fullname: Mercadante – volume: 9 start-page: 1003 year: 2020 ident: R2-20240901 article-title: Careful breakthrough cancer pain treatment through rapid-onset transmucosal fentanyl improves the quality of life in cancer patients:Results from the BEST multicenter study publication-title: J Clin Med doi: 10.3390/jcm9041003 contributor: fullname: Cuomo – volume: 110 start-page: 271 year: 2013 ident: R3-20240901 article-title: Fentanyl for the treatment of tumor-related breakthrough pain publication-title: Dtsch Arztebl Int contributor: fullname: Bornemann-Cimenti – volume: 6 start-page: 305 year: 2005 ident: R10-20240901 article-title: Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines publication-title: Pain Med doi: 10.1111/j.1526-4637.2005.00045.x contributor: fullname: Aronoff – volume: 41 start-page: 661 year: 2002 ident: R11-20240901 article-title: Oral mucosal drug delivery:Clinical pharmacokinetics and therapeutic applications publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200241090-00003 contributor: fullname: Zhang |
SSID | ssj0001939919 |
Score | 2.312029 |
Snippet | ABSTRACT Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional... Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain management... Background: Breakthrough pain in cancer patients is a common and distressing symptom that significantly impacts their quality of life. Traditional pain... |
SourceID | doaj gale crossref |
SourceType | Open Website Aggregation Database |
StartPage | 145 |
SubjectTerms | breakthrough pain cancer pain Care and treatment Fentanyl fentanyl citrate Home care Medical research Medicine, Experimental opioids oral transmucosal fentanyl citrate Pain Patient compliance rapid onset |
Title | Oral transmucosal fentanyl citrate as breakthrough pain relieving medication: A pilot study |
URI | https://doaj.org/article/15bc6e6ea8fa441a999cf824c8496ad1 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09T8MwELVQJxYEAkSgIA9IsIQmjhM7bAW1qhhgoaISg-X4Q6rol0oZ-PfcOQHSiYXFUhwP1rvY986-vCPkMk9tbnzG40R7LGGmbayBZcSu5B6v_SrhQoLsYzEa84dJPmmV-sKcsFoeuAaul-aVKVzhtPQaXLcGQmO8ZNxIXhba1oFPwlrBVDhdKcHxhqoeDBhGDH5P1Lo-PE2ynpmvVzfYKMEU41suKSj3N_tzy9MM98leQxFpv57aAdlxi0Py-rSGvg16ljkmmcODx7TvxeeMmmmQmKX6nUKAq9-a2jt0BVE_XTtgmXhqQMM1ejDELe3T1XS23NCgLntExsPB8_0obgojxAYVzmAHK6X10maCA8yMAcXxSGW4zqVPAGEnmMlcmlYW_X0JLihxlqU2SO1UMjsmncVy4U4ItZUstMmFKzTjHq_JdFIlWhQi06JK04hcf2OjVrX-hYK4AWFUAcFfGCNyh9j9DEPh6tAB5lSNOdVf5ozIFSKvcHkBdkY3fwnAbFGoSvUxwIRdVmYR6W6NhGVhWq9P_2M2Z2SXAYmp03O7pLNZf7hzICGb6iJ8b9C-ZIMvgqzahw |
link.rule.ids | 314,780,784,864,2102,27924,27925 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+transmucosal+fentanyl+citrate+as+breakthrough+pain+relieving+medication%3A+A+pilot+study&rft.jtitle=Current+medicine+research+and+practice&rft.au=Naresh+Dua&rft.au=Randheer+Kumar+Annaram&rft.au=Pradeep+Jain&rft.au=Priya+Yadav&rft.date=2024-07-01&rft.pub=Wolters+Kluwer+Medknow+Publications&rft.issn=2352-0817&rft.volume=14&rft.issue=4&rft.spage=145&rft.epage=149&rft_id=info:doi/10.4103%2Fcmrp.cmrp_72_24&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_15bc6e6ea8fa441a999cf824c8496ad1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-0817&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-0817&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-0817&client=summon |